Burkitkan received his master in biomedical science in Genetic, Immunology, Cancer from Rouen University, France, on the following topic: “Effects of Combined Treatment of Retinoic Acid and Arsenic Trioxide on the Differentiation of Neuroblastoma Cells” under the supervision of Dr. Isabelle Dubus and Dr. Petit Alexandre.
The main aim of his project was to study the synergistic action between Retinoic Acid and Arsenic Trioxide on the differentiation of neuroblastoma cell lines (SH-SY5Y, IGR-N-91, LAN-1) and to study the potential signaling pathways activated by these molecules. His study results showed that PIK3/AKT signaling pathway is activated by these molecules, but this activation is not necessary for the differentiation of neuroblastoma cells by using specific inhibitors of PI3K. Furthermore, he showed that the combination of these two molecules at lower concentrations has a cooperative action on the differentiation by studying the markers of neuronal cell differentiation like neuritogenesis, NFM expression.
Average length of neurites in each cells after 72h of treatment with Retinoic Acid (ATRA) and Arsenic trioxide (As2O3), alone or in combination. *p≤ 0.05, ** : p≤ 0.01 when compared to control ; #: p≤ 0.05 vs separate treatment in low doses.
Burkitkan is now working on the effect of newly synthesized chemical drug on different cancer cell lines within the Lam’s group.